Progress of Waldenstrom macroglobulinemia / 白血病·淋巴瘤

ABSTRACT

Waldenstrom macroglobulinemia (WM) is a rare and incurable indolent lymphoma, characterized by serum monoclonal IgM. Whole-genome sequencing has showed that MYD88 and CXCR4 gene mutations are the most common molecular genetic changes in WM. In recent years, with the development of next-generation sequencing and other technologies, the research on the pathogenetic mechanism of WM has been continuously explored. Clinical trials of Bruton tyrosine kinase (BTK) inhibitors, proteasome inhibitors and other new drugs have been continuously carried out, improving the prognosis of WM. This paper reviews the latest research on treatment and prognosis analysis of WM in the 61st American Society of Hematology Annual Meeting.